Diamedica Therapeutics Inc (NASDAQ: DMAC) has updated its Phase 2 REDUX Study In CKD. Over the years, this clinical-stage biopharmaceutical company has worked on finding working solutions for cardio-renal diseases and various neurological disorders. The company is quite impressed with the associated Positive Interim Results.
The study’s activities and achievements
Today’s announcement tells a lot about its success in its Phase 2 REDUX trial of DM199, a step it considers crucial in dealing with chronic kidney disease (CKD). It was an undertaking that focused on three populations struggling with the high unmet or are medical needs.The conditions included: diabetic kidney disease (DKD) (Cohort 3, n=28), IgA Nephropathy (IgAN) (Cohort 2, n=16); and African Americans (AA), non-diabetic and hypertensive (Cohort 1, n=12).
What are the merits of DM199
The trial shows several merits for turning to DM199, but the most important happens to be the product’s demonstration of some clinically meaningful improvements. The significant areas of focus have been the kidney function in Cohorts 1 and 2. The study focused on ways to achieve some critical functionality changes. It focuses on two main areas, and those happen to be the decreasing urine albumin-to-creatinine ratio (UACR) and the stabilization of the estimated glomerular filtration rate (eGFR).
The President and Chief Executive Officer of DiaMedica, Rick Pauls, seems impressed with the data fetched. He believes that the data depicts an outstanding biologic activity of the recombinant KLK1 (DM199).
He opines, “We are optimistic as we continue the trial of DM199 in IgAN and hypertensive African Americans with CKD and begin the pivotal Phase 2/3 study in acute ischemic stroke later this summer.”
The Professor of Medicine at Indiana University School of Medicine, Dr. Rajiv Agarwal, admits that the data in question is only preliminary. However. He considers it a good indicator of the role that DM199 can play in treating diverse conditions.